Our vision of innovation

Innovation is not an option in the healthcare field, especially when it comes to in vitro diagnostics – it’s a requirement. Innovation is essential to meet public health challenges across the globe. 

Innovation, a priority for bioMérieux

From the start, bioMérieux has invested in sectors where our expertise differentiates us and generates real added value. This has enabled us to become leaders in several areas: clinical microbiology, the syndromic diagnosis of infectious diseases, and industrial microbiological control.

Our teams are working to develop diagnostic tests to maintain this standard of excellence and provide solutions to address new public health challenges – for example, the emergence of new infectious diseases, antimicrobial resistance, the fight against sepsis, microbiological quality control in agri-food and cosmetic products, as well as sterility testing for pharmaceutical products – with two priority objectives:

  • Increasing the medical value of diagnostics with tests that support decision making and generate clinical value for physicians by identifying and characterizing disease agents with greater precision;
  • Providing faster, more reliable results to improve health outcomes for patients and to protect consumer safety.

Our core focus: the patient and the consumer

In the clinical and the industrial fields, innovation for bioMérieux aims to provide laboratories with results as quickly as possible, everywhere in the world, to improve the health of patients and ensure the safety of consumers.

What sets us apart is our holistic approach to diagnostics and our portfolio of complementary solutions. As pure players of in vitro diagnostics, we develop solutions based on our expertise in its three key areas: microbiology, molecular biology and immunoassays.

For clinical applications, the combination of these three types of expertise makes it possible to provide high medical-value solutions at the best cost. Take the case of sepsis, where every minute counts when it comes to diagnosing the infection and determining the response by the host, i.e., the patient. With our highly diverse, complementary product offering, we can give healthcare professionals the essential information they need to make the appropriate medical decision as quickly as possible and improve the patient’s health.

Our research project choices are guided by paying attention to our customers’ needs as well as our technology watch and technical watch. In the face of a revolution in diagnostics using information technology, we are intensifying our research in the fields of genomic sequencing, ultra-fast microbiology and smart data.


Milestones mark progress to serve public health

Our recent launches in the clinical field:

  • Complementary diagnostic tests for the detection of the SARS-CoV-2 virus responsible for COVID-19:
  • ARGENE® SARS-COV-2 R-GENE®, a real-time PCR test that can be used to test a large number of patient samples simultaneously;
  • ARGENE® SARS-COV-2 RESPI R-GENE®, a real-time PCR test for the detection of SARS-CoV-2, influenza viruses A and B, RSV (human respiratory syncytial virus) and hMPV (human metapneumovirus) from a single sample ;
  • BIOFIRE® COVID-19, an automated real-time PCR test based on the BIOFIRE® FILMARRAY® 2.0 and TORCH technology, which can be used for the individual diagnosis of a patient in an emergency setting;
  • expanded version of the BIOFIRE® Respiratory Panel, updated to include the detection of SARS-CoV-2, in addition to the 21 pathogens that most frequently cause respiratory infections, with detection in approximately 45 minutes;
  • VIDAS® SARS-COV-2 IgM and SARS-COV-2 IgG, two serological tests to detect the immune response to SARS-CoV-2 infection.
  • BIOFIRE® Pneumonia panels, which report results in semi- quantitative levels for 15 bacteria in order to help clinicians to differentiate micro-organisms that are naturally present in the body from those responsible for the infection.
  • VIDAS® TB-IGRA (Interferon-Gamma Release Assay), innovative and fully-automated test to diagnose latent TB infection.
  • VIDAS® DENGUE NS1 Ag, VIDAS® Anti-DENGUE IgM and VIDAS® Anti-DENGUE IgG tests, innovative and fully-automated assays to diagnose dengue infection.


In the industrial field:​

  • BIOFIRE® MYCOPLASMA, a rapid and simplified detection test for mycoplasmas in the manufacture of pharmaceuticals products used for biotherapies;
  • ENDOZYME® II GOan innovative test based on recombinant proteins for the detection of endotoxins in pharmaceutical grade water, injectable drugs and other pharmaceutical products;
  • Culture bottles BACT/ALERT® VIRTUO® BPA and BPN for use by blood banks;
  • GENE-UP® CRONOBACTER, a test to detect the pathogen Cronobacter spp for products in the agri-food industry.